Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.

Br J Haematol · 2023 · PMC10091809 · PMID 36205375

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

A highly significant difference was noticed in PFS and OS among responders versus non‐responders, suggesting the improved OS is likely attributable to belantamab mafodotin therapy.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.